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Csilla Özvegy-Laczka, and Barbara Zdrazil*
Cite This: J. Chem. Inf. Model. 2021, 61, 3109−3127 Read Online
ACCESS Metrics & More Article Recommendations *sı Supporting Information
ABSTRACT: Hepatic organic anion transporting polypeptides
OATP1B1, OATP1B3, and OATP2B1are expressed at the
basolateral membrane of hepatocytes, being responsible for the
uptake of a wide range of natural substrates and structurally
unrelated pharmaceuticals. Impaired function of hepatic OATPs
has been linked to clinically relevant drug−drug interactions
leading to altered pharmacokinetics of administered drugs.
Therefore, understanding the commonalities and differences across
the three transporters represents useful knowledge to guide the
drug discovery process at an early stage. Unfortunately, such efforts
remain challenging because of the lack of experimentally resolved
protein structures for any member of the OATP family. In this
study, we established a rigorous computational protocol to generate and validate structural models for hepatic OATPs. The
multistep procedure is based on the systematic exploration of available protein structures with shared protein folding using normal-
mode analysis, the calculation of multiple template backbones from elastic network models, the utilization of multiple template
conformations to generate OATP structural models with various degrees of conformational flexibility, and the prioritization of
models on the basis of enrichment docking. We employed the resulting OATP models of OATP1B1, OATP1B3, and OATP2B1 to
elucidate binding modes of steroid analogs in the three transporters. Steroid conjugates have been recognized as endogenous
substrates of these transporters. Thus, investigating this data set delivers insights into mechanisms of substrate recognition. In silico
predictions were complemented with in vitro studies measuring the bioactivity of a compound set on OATP expressing cell lines.
Important structural determinants conferring shared and distinct binding patterns of steroid analogs in the three transporters have
been identified. Overall, this comparative study provides novel insights into hepatic OATP-ligand interactions and selectivity.
Furthermore, the integrative computational workflow for structure-based modeling can be leveraged for other pharmaceutical targets
of interest.
■ INTRODUCTION
Solute carriers (SLC) are increasingly recognized for their
pivotal role in compound pharmacokinetics, given their
involvement in drug absorption, disposition, metabolism,
elimination, clinically relevant drug−drug interactions, and
related organ toxicities.1,2 Here, we focus on a triad of organic
anion transporting polypeptides of the SLCO (SLC21)
superfamily. OATP1B1 (SLCO1B1 gene), OATP1B3
(SLCO1B3 gene), and OATP2B1 (SLCO2B1 gene) are
expressed at the basolateral membrane of hepatocytes,
mediating the cellular uptake of a broad spectrum of
endogenous substrates and xenobiotics.3−5 Endogenous
compounds include bilirubin, bile acids, steroid conjugates,
and hormones. Drugs transported by hepatic OATPs are
structurally and functionally quite heterogeneous, such as
statins (pitavastatin, rosuvastatin, fluvastatin),6 antihistamines
(fexofenadine),7 anticancer agents (SN-38, paclitaxel, imati-
nib),8 antibiotics (rifampicin, clarithromycin, benzylpenicil-
lin),9 or anti-inflammatory drugs (ibuprofen, diclofenac,
lumiracoxib).10 OATP-mediated drug−drug interactions rep-
resent a challenge for drug development. Therefore, the U.S.
Food and Drug Administration recommends testing of novel
drug candidates for their potential interactions with hepatic
OATPs. The computational prediction of whether a certain
drug might interact with hepatic OATPs is a promising
approach at the early stage in the drug discovery pipeline to
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minimize the risk of attrition. However, these efforts remain
challenging, mainly because of the lack of experimental protein
structures for any member of the OATP family. In general, the
sequence identity of hepatic OATPs to the closest structural
analogs that have been resolved experimentally, does not
exceed 16%, which makes the generation of the high-quality
structural models a nontrivial task. Homology modeling
becomes error-prone below 30% sequence identity (referred
to as “twilight zone” protein modeling). In recognition of this
challenging modeling task, we decided to use a threading
approach by applying secondary structure prediction to
identify the closest structural analog to be used as a template
for modeling.11 To date, the majority of computational studies
involving hepatic OATPs have been ligand-based, including
different QSAR models,12−18 proteochemometric models,12,19
ligand-based pharmacophore models,20 and substructure
analyses.15
OATPs are glycoproteins containing 643−722 amino acids.
Hydropathy analysis shows 12 transmembrane helices
(TMHs) interconnected by intracellular (IC) and extracellular
(EC) loops,21 corresponding to the major facilitator super-
family (MFS) fold.22 MFS proteins contain multiple binding
sites capable of recognizing structurally unrelated compounds.
A large EC loop between TMH9 and TMH10 contains 11
cysteine residues which form disulfide bonds, resembling the
Kazal-type domain of serine protease inhibitors (see Figure
1).23 Other important structural features are the N-
glycosylation sites in the EC loops 2 and 5,4 phosphorylation
sites at the N- and C-terminus,24 and the consensus sequence
region spanning EC loop 3 and TMH6.25 The first structural
models for OATP1B3 and OATP2B1 date back to 2005.22 On
the basis of the comparison of OATP1B3 and OATP2B1
structures, ARG181 was suggested to contribute to OATP1B
substrate specificity, while HIS579 was suggested as a
structural determinant conferring OATP2B1 activity. Mandery
et al.26 published newer structural models for OATP1B3 and
OATP2B1 in 2011. Comparative analysis revealed that
LYS361 and LYS399 are highly conserved across the OATP
superfamily of membrane transporters, where LYS361 is
pointing toward the translocation pore.26 In another study,
mutagenesis experiments supplemented by structural model
generation showed that several residues at THM2 of
OATP1B1 (ASP70, PHE73, GLU74, GLY76) are implicated
in transport function.27 Moreover, two distinct binding sites
(low- and high-affinity binding site) for estrone-3-sulfate (E-3-
S) were identified in that study. Another structure-based
modeling study combined with alanine-scanning experiments
identified the importance of TMH11 for OATP1B1-mediated
ligand uptake.28 Further, Glaeser et al. used structure-based
modeling supported by experimental validation to show the
importance of a positive charge at position 41 and 580 for
OATP1B3 transport function.29 Gui and Hagenbuch created a
3D structure of OATP1B3 and identified several crucial
residues at TMH10 (TYR537, SER545, and THR550), which
were subsequently analyzed via site-directed mutagenesis. In a
recent study by Khuri et al., a combination of structure-based
modeling and machine learning approaches was used to
identify novel OATP2B1 inhibitors.30
An illustrative depiction of the overall protein organization
into 12 TMHs and several IC and EC loops with an overview
of amino acid residues with an experimentally confirmed
involvement in ligand binding or transporter function is
provided in Figure 1. Corresponding references are given in
Table S1.
In this Article, we present an integrative computational
pipeline for retrieving high quality structural models for
OATP1B1, OATP1B3, and OATP2B1. The models were used
to elucidate binding modes for steroid analogs highlighting
commonalities and differences between the three transporters.
To the best of our knowledge, this is the first comparative
structure-based modeling study including all three hepatic
OATPs.
Molecular determinants contributing to OATP-steroid
interactions (and selectivity) have been analyzed in detail in
our previous paper.15 Here, we are focusing on structural
determinants as revealed by molecular docking to the
developed transporter protein models, revealing distinct
binding sites and ligand-transporter interactions. The computa-
tional findings presented herein have been validated retro-
spectively by comparison to published mutagenesis data and
known single nucleotide polymorphisms. Structural models
generated herein can be leveraged for, for example, virtual
screening purposes to identify novel OATP interacting
compounds. An in-house data set of new 13α-estrone
derivatives with measured IC50 values on OATP1B1,
OATP1B3, and OATP2B1 has been used in order to augment
the compound data set from public sources with compounds
showing a tendency toward higher affinity for OATP2B1
(which is to date the least studied transporter of the three
hepatic OATPs).31 A special focus of the developed pipeline is
ensemble docking. Inclusion of protein conformational
flexibility is expected to increase confidence of the applicability
of the structural models for docking. The application of
ensemble docking in this study was motivated by the
assumption that selectivity of SLC transporters might not be
exclusively modulated by sequence variability but also by
differences in conformational flexibility. Therefore, the final
structural models were prioritized according to their ability to
enrich known active compounds among a pool of known
inactive compounds and decoys. To create a representative
subset of OATP conformations, normal-mode analysis (NMA)
was applied for available MFS structures to detect soft modes
of motion which cover conformational diversity of MFS
transporters (so-called “signature dynamics”).32 The pipeline
presented here is versatile enough to be deployed for other
protein targets of interest and was exclusively built upon freely
available tools and software (pGenThreader,33 Modeler,34
Figure 1. Schematic overview of relevant amino acid residues
reported in the literature for the transport function or specificity of
OATP1B1 (blue), OATP1B3 (magenta), and OATP2B1 (green).
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ProDy,35 PHENIX,36 GROMACS,37 AutoDock Vina,38
PyMol,39 KNIME,40 Open Babel41), which enables full
adaptability and reusability.
■ MATERIALS AND METHODS
All data, code, workflows, and models used or created in this
study are available from an open GitHub repository: https://
github.com/AlzbetaTuerkova/EnsembleDocking.
Comparative Modeling of Hepatic OATPs. Structural
templates were detected by the fold-recognition tool
pGenThreader33 (default settings).
The fucose transporter in an outward-open conformation
(FucP, PDB ID 3o7q, 3.14 Å resolution)42 possessing major
facilitator superfamily (MFS) fold was identified as a high-
quality template for OATP1B1 (p-value ≤ 0.0001, prediction
score 75, 14.5% sequence identity), OATP1B3 (p-value ≤
0.0001, prediction score 75, 15.6% sequence identity), and
OATP2B1 (p-value ≤ 0.0001, prediction score 93, 15.2%
sequence identity), respectively (see Table S2). In addition to
a high prediction score for all the three transporters, the FucP
template was selected because of its reasonable crystal
structure resolution (3.14 Å), and an outward-open conforma-
tional state, which appears advantageous for studying ligand
recognition.
PROMALS3D was used to generate multiple structure-to-
sequence alignments between FucP and human OATP
structures.43 The generated alignment was subjected to manual
adjustments. Pairwise template-to-sequence alignments are
available in the GitHub repository (https://github.com/
AlzbetaTuerkova/EnsembleDocking; OATP1B1-FucP,
OATP1B3-FucP, and OATP2B1-FucP). Because of the lack
of structural templates for extra- and intracellular domains, our
models cover the transmembrane region only. Amino acid
residue numbers in the FucP template used for comparative
modeling are the following: 22−56, 60−114, 115−177, 200−
239, 242−290, 292−409, and 412−434. Corresponding
regions in OATP1B1, OATP1B3, and OATP2B1 are listed
in Table S3.
Enrichment docking into an ensemble of OATP con-
formations was conducted to prioritize the best model per
transporter. Multiple OATP structures with various degrees of
global (i.e., backbone conformer) and local (i.e., side-chain
rotamer) flexibility were modeled. A similar strategy to the one
applied by Carlsson et al.44 was adopted by performing NMA
on the template structure. The modeling protocol introduced
by Carlsson et al. has been expanded to perform more rigorous
sampling of the protein conformational space. First, anisotropic
network models (ANM) were calculated for all the available
experimental structures possessing MFS fold to identify
dominant motions within the whole protein family (so-called
“signature dynamics”, for details see the Signature Dynamics of
Major Facilitator Superfamily Proteins section). Second,
alternate conformations for FucP were calculated by including
the implicit membrane model (see the Conformational
Sampling of the FucP Template section). NMA calculations
were performed by using the ProDy software (freely available
at http://prody.csb.pitt.edu/).35
Signature Dynamics of Major Facilitator Superfamily
Proteins. The FucP template (PDB ID: 3o7q) was selected as
a reference query for the retrieval of structurally analogous
proteins by using the Dali server.45 In total, 92 protein
structures with a shared fold were identified in the Protein
Data Bank (PDB). Sequence identity between the structural
analogs and the FucP structure was set to 10% to reduce the
large pool of detected protein structures to a manageable
amount. After data reduction, 45 PDB structures were retained
in the structural ensemble. Twenty Gaussian Network Models
(GNMs) modes per every protein structure were calculated at
Cα carbon resolution. Calculated GNMs were analyzed with
respect to commonalities and differences in the mode shapes,
shared covariance between residues, cross-correlations, as well
as mean square fluctuations. In addition, the similarity of
protein structures in the structural ensemble was evaluated
based on sequence (Hamming distance), 3D structure
(RMSD), and their intrinsic dynamics (arccosine function of
the covariance overlap). Specifically, the lowest frequency
mode for each protein structure was used for this comparative
analysis.
Conformational Sampling of the FucP Template. In this
study, an implicit membrane model was incorporated into the
ANM calculations.46 The restoring force for any protein
displacement was set to be 16-times greater in the x- or y-
direction than in the z-direction. The scaling factor was applied
to preferentially restrain radial motions. Such defined restraints
aim to mimic the constraints imposed by the membrane on the
conformational dynamics of membrane proteins. Boundaries
for the implicit membrane effect have been set to a distance of
±15.35 Å from the membrane core, as predicted by the OPM
server.47
To prevent nonphysical distortions or bond stretching,
individual residues were coarse-grained into predefined rigid
blocks.48 Here, an assignment of residues into rigid blocks was
done based on the hydrogen-bond estimation (DSSP)
algorithm.49 Rigid block decomposition led to 135 blocks.48
One thousand alternate conformations were sampled along the
two lowest frequency modes. In the next step, sampled
conformers were refined by performing energy minimization in
GROMACS 5.1.4,37 using the steepest descent algorithm in
the AMBER99SB-ILDN force field.50 The convergence
criterion was set to a maximum force <100.0 kJ/mol/nm. To
reduce the large pool of conformational ensembles while
preserving variance, only conformations with a cutoff distance
of 3 Å from the average were kept resulting in 20 distinct
conformers used for OATP structural modeling.
Construction of OATP Structural Models in Different
Conformations. On the basis of the 20 FucP template
conformers, 60 distinct models per transporter were calculated,
following these consecutive steps:
(1) 20 different template conformers with an average RMSD
of 3 Å were selected from the template conformational
ensemble (counting 1000 conformers in total, see
previous section).
(2) 100 comparative models per distinct template conformer
were generated resulting in 2000 different models.
(3) N- and C- termini in helix breaks were acetylated
(shortcut “ACE” in Modeler 9.17) and methylamidated
(shortcut “CT3” in Modeler 9.17). Energy minimization
of the comparative models was performed in GRO-
MACS using the same settings as described in section
2.1.2.
(4) Minimized models were ranked on the basis of the
MolProbity51 score calculated by using the PHENIX
software.36
Validation analysis within the MolProbity tool consists of
four consecutive steps: (a) Addition of hydrogen atoms. Asn/
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Gln/His flips are automatically corrected and −OH, −SH, and
−NH3 groups are rotationally optimized. (b) All-atom contact
analysis by probing the amount of overlap between the
nonbonded atoms. The “clashscore” generated via contact
Table 1. In-House Data Set of Steroid Analogs Used to Characterize Binding Sites of OATP1B1, OATP1B3, and OATP2B1a
aChemical structures and bioactivity values (IC50 values in μM measured for the respective transporter) are given.
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analysis corresponds to the number of significant clashes (non-
H-bond atom overlap > 0.4) per 1000 atoms. (c)
Ramachandran and rotamer analyses of backbone and side-
chains, respectively. (d) Covalent-geometry analysis by
checking the outliers of backbone bond-lengths and bond-
angles. The final MolProbity score unites all individual quality
metrics into a single value. The MolProbity score was
calculated for all 2000 models to filter out low-quality models.
Only three top-ranked rotamers per distinct conformer were
retained for enrichment docking, resulting in 60 distinct
models per transporter that were used for enrichment docking.
Retrieving Ligand−Protein Interactions by Molecular
Docking. Preparation of the Docking Library. Compounds
with measured bioactivities (Km, IC50, Ki, and EC50 bioactivity
end points or percentage inhibition values) on OATP1B1 (n =
440 compounds), OATP1B3 (n = 936 compounds), or
OATP2B1 (n = 173 compounds) were collected from the
open domain by utilizing a KNIME workflow, which collects
data from five independent data sources as described in
Tuerkova et al.15 In addition, compounds from two of our
recently published papers reporting pharmacological measure-
ments for novel 13α-estrone derivatives were included.52,53
Experimental measurements for 16 13α-estrone derivatives
have been extended in this study in order to report activity on
all three transporters. IC50 values were calculated based on
transport inhibition measurements (see below) by Hill1 fit,
using the Origin Pro8.6 software (OriginLab Corporation,
Northampton, MA, US).
13α-Estrone derivatives characterized in this study possess
two major variations: (1) phosphorylation and (2) halogen-
ation at either the R-2 or R-4 position of the steroidal core
scaffold. The R3̅ position in the in-house data set is composed
of a hydroxyl, methoxy, or benzyloxy moiety (see Table 1).
For the whole data set (public and in-house), frequencies of
variations at different R-group positions (Figure S1) are in
accordance with our previously published study on OATP
ligand profiles.15
For the first two rounds of docking, for extracting the best
protein model for each transporter, all compounds with
bioactivity measurements were usedindependent of their
core molecular scaffold. The only exception was the in-house
data set of 13α-estrone derivatives, which was used as a
validation set. By including compounds with diverse core
scaffolds, an unbiased selection of the “best” model (according
to ligand enrichment) can be guaranteed. It has to be noted
that this training data set did only contain a few compounds
with a steroid scaffold for OATP1B1 (7 compounds) and
OATP1B3 (4 compounds), but no steroidal structure for
OATP2B1, which makes a bias of the model selection toward
structures that better accommodate steroids less likely
(especially in case of OATP2B1 this bias is impossible).
To obtain the recommended ratio of actives:inactives(/
decoys) of 1:36, the data sets were enriched by decoys from
DUD-E.54 A compound was defined as active if the bioactivity
value was ≤1 μM in case of OATP1B1 and OATP1B3 and ≤5
μM in case of OATP2B1 (due to a smaller amount of data)
and inactive if the activity value was >10 μM. Compounds with
bioactivities falling into the region between >1 or >5 and ≤10
μM were excluded from the data set. If a compound occurred
in different protonation states at pH 7.0 (±2.0), each protomer
was considered as a separate compound for docking. The
resulting docking library consisted of 57 actives, 917 inactives,
and 1223 decoys for OATP1B1; 25 actives, 900 inactives, and
no decoys for OATP1B3; and 12 actives, 153 inactives, and
279 decoys in case of OATP2B1. Ligand conformers were
generated by the LigPrep tool in Maestro (version 19−1;38
OPLS3e force field). Ionization states were generated at target
pH 7.0 ± 2.0 (Epik algorithm in Maestro).
Enrichment Docking for Model Prioritization. Compounds
were docked into the top 60 models per transporter by using
the program Autodock Vina 1.1.2.38 Exhaustiveness of the
global search was set to 10. Ligand enrichment was calculated
in R3̅.4.2 (available at https://www.r-project.org/). The area
under the curve (AUC) and the enrichment factor (EF) at the
top 1% of the data set (EF 1%) was calculated as a metric for
ligand enrichment. In the first round of docking calculations,
the entire transmembrane region (encompassing all 12 TMHs)
was defined as a putative binding site. Models were ranked on
the basis of their AUC values. Five top-ranked models per
transporter were retained for further inspection. AUC values
for the preselected models can be found in Table S4. For
performing the second round of docking calculations, the
putative protein binding site was further restricted. Specifically,
the contact surface area between the active compounds docked
in the first round was calculated, and the calculated region was
used as search space in the second round of enrichment
docking calculations. The procedure is visualized in Figure S2.
The top final model was selected on the basis of the ranking of
both AUC and EF 1% of the data set.
The stepwise computational procedure for structural model
generation is depicted in Figure 2.
Molecular Docking of Steroid Analogs. The 16 13α-
estrone derivatives with in-house measured activity on
OATP1B1, OATP1B3, and OATP2B1 used in this study are
listed in Table 1. Supplementary File S4 in the GitHub
reposi tory (https://github.com/AlzbetaTuerkova/
EnsembleDocking) lists steroidal compounds retrieved from
public data sources along with their measured bioactivities (17
compounds). Correct stereochemistry of the steroidal nucleus
was verified by comparing to experimentally resolved steroids
in the Protein Data Bank (PDB) which were obtained via
RESTful web services in KNIME40 (analogous to previously
published work by our group).55
Autodock Vina 1.1.2.38 was used to dock steroid analogs.
Ten binding modes were sampled. Exhaustiveness of the
search was set to 20. To map possible interaction sites for
steroid analogs, the entire transmembrane region was defined
as a putative binding site.
Docked poses were analyzed via hierarchical pose clustering
as follows: (1) A docked ligand structure was reduced to its
core Murcko scaffold56 (saved in pdbqt format), (2) a pdbqt
file with a core scaffold was converted into a mol file format
using Open Babel 2.4.1.,41 (3) the maximum common




SMARTS, see Figure S1) for all retrieved core scaffolds was
calculated (using the FindMCS functionality in RDKit; bond
order kept flexible) by using an in-house script (available as
Supplementary File S5 in the GitHub repository (https://
github.com/AlzbetaTuerkova/EnsembleDocking)), (4) output
coordinates were saved in xyz format and converted back to
pdbqt format using OpenBabel 2.4.1. (5) MCSs were loaded
into PyMOL,39 and (7) the agglomerative hierarchical
Journal of Chemical Information and Modeling pubs.acs.org/jcim Article
https://doi.org/10.1021/acs.jcim.1c00362
J. Chem. Inf. Model. 2021, 61, 3109−3127
3113
clustering algorithm within the PyDRA plugin was used to
calculate average distances (distance cutoff set to 2 Å).
Cluster analysis was performed in KNIME 4.1.2.40
Compounds were analyzed by calculating protein−ligand
interaction fingerprints (PLIFs) in MOE.57 H-donor (cutoff
0.5−1.5 [kcal/mol]), H-acceptor (cutoff 0.5−1.5 [kcal/mol]),
ionic attraction (cutoff 0.5−3.5 [kcal/mol]), metal ligation
(cutoff 0.5−3.5[kcal/mol]), and arene attraction (cutoff 0.5−
1.0 [kcal/mol]), were defined as distinct interaction types used
in the calculation. The pocket volume was calculated via the
open-source POVME binding pocket analysis software.58 The
radius of gyration was calculated by using the gyradius
functionality within the Psico module (a PyMOL extension).
Transport Inhibition Experiments for 13α-Estrone
Derivatives. 13α-Estrone derivatives were synthesized pre-
viously, as described in Joj́aŕt et al.52 and Bacsa et al.,59 20 mM
stocks in DMSO were stored for further usage at −20 °C.
A431 cells overexpressing OATPs, OATP1B1, OATP1B3, or
OATP2B1 or mock transfected controls were generated
previously.60 A431 cells were maintained in DMEM medium
(Thermo Fischer Scientific, Waltham, MA, US) supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, 100 units/mL
penicillin, and 100 μg/mL streptomycin at 37 °C with 5%
CO2. The interaction of 13α-estrone derivatives with OATPs,
1B1, 1B3, and 2B1 was measured in A431 cells overexpressing
the given OATP using the previously identified OATP1B and
OATP2B1 substrate pyranine (8-hydroxypyrene-1,3,6-trisul-
fonic acid trisodium salt, Sigma, Merck, Hungary). The uptake
of pyranine was measured on microplates based on the method
developed by us previously.60,61
Briefly, 1 day prior to the uptake measurement cells (8 × 104
cells/well in 200 μL DMEM) were seeded on 96-well plates.
On the following day, the medium was removed, and the cells
were washed three times with 200 μL of phosphate-buffered
saline (PBS, pH 7.4) and preincubated with 50 μL of uptake
buffer (125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM
KH2PO4, 12 mM MgSO4, 25 mM MES (2-(N-morpholino)-
ethanesulfonic acid, and 5.6 mM glucose, pH 5.5) with or
without increasing concentrations of the tested compounds.
The reaction was started by the addition of 50 μL of uptake
buffer containing pyranine in a final concentration of 10 μM
(OATP1B1) or 20 μM (OATP1B3 and OATP2B1). Cells
were incubated with the dye at 37 °C for 15 min (OATP1B1
and OATP2B1) or 30 min (OATP1B3), after which the
supernatant was removed, and the cells were washed three
times with 200 μL of ice-cold PBS. Fluorescence (in 200 μL of
PBS/well) was determined in an Enspire plate reader
(PerkinElmer, Waltham, MA, Ex/Em = 403/517 nm).
OATP-dependent transport was calculated by extracting
fluorescence measured in mock transfected cells. Transport
activity was calculated based on the fluorescence signal in the
absence (100%) of the tested compounds. Experiments were
repeated at least three times on cells deriving from different
passages.
IC50 values were calculated by Hill1 fit, using the (OriginLab
Corporation, Northampton, MA, US).
■ RESULTS AND DISCUSSION
Insights from Conformational Sampling of Exper-
imentally Resolved MFS Structures and Ensemble
Docking into OATP Structural Models. Biologically
relevant motions, such as protein conformational changes
happen at time scales in the range of micro- to milliseconds or
Figure 2. Major steps applied to retrieve structural models: In step 1,
a fold recognition algorithm (here: pGenThreader) is used to identify
the protein fold from the target sequences. Step 2 involves alignment
of available protein structures possessing the desired fold. NMA is
performed to identify conserved motions shared across the proteins
with the same fold (here, called signature dynamics). In step 3,
structural models (here, OATP1B1/OATP1B3/OATP2B1) are
generated via a multistep procedure; First, the template structure
(here, fucose transporter) is decomposed into individual rigid blocks
via the hydrogen bond estimation algorithm (DSSP). Next, a scaling
factor is applied to prioritize motions in the radial direction, which
mimics the membrane environment (hence, implicit membrane
model). Alternate conformers of the template structure are sampled
via NMA. Structural models (here, OATP1B1/OATP1B3/
OATP2B1) are subsequently built on the basis of different template
conformations. For each template conformer, 20 structural models
possessing 20 different side-chain rotamers are calculated. Enrichment
docking (step 4) is performed in two consecutive steps: First, the
entire transmembrane region is defined as a putative binding site (as
indicated by the cube). Known active ligands and inactives/decoys are
docked and the models are subsequently ranked on the basis of their
AUC values. The top five models are retained. The contact surface
area accommodating known actives from the first round of docking is
calculated (visualized as pink mesh) and further used to restrict the
search space for the second round of enrichment docking calculations.
After the enrichment, docking is repeated into the top five models,
and the best model is prioritized on the basis of its AUC value. In case
no significant difference between AUC values was observed, the EF
1% was used as an additional metric to prioritize models.
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even seconds and, therefore, generally cannot be studied by
classical molecular dynamics (MD) simulations. By using
normal-mode analysis (NMA), functional protein motions can
be captured by global (soft) modes, which represent collective
motions of entire protein (sub)domains. In this study, the
motivation for inclusion of NMA was 2-fold: (1) To compare
normal modes for available structures of the major facilitator
superfamily (MFS) members (45 structures) from the Protein
Data Bank (PDB) and, thus, identify functionally important
protein motions and (2) to sample alternate template
conformers.
In the former case (1), our intention was to explore how
intrinsic protein dynamics might diverge across a protein
family with a shared fold (so-called signature dynamics).
Global fluctuations shared across the MFS proteins might
deliver useful insights into the transport mechanism. In the
latter case (2), we incorporated the knowledge about MFS
dynamics from step 1 into our ensemble docking strategy in
such a way that anisotropic network models (ANMs) for the
selected template (here, FucP; PDB ID 3o7q) were calculated.
Signature Dynamics of MFS Transporters. To assess the
feasibility of the elastic network models for exploring the
intrinsic dynamics of MFS proteins, root-mean-square
fluctuations (RMSF) derived from NMA can be compared
with crystallographic B-factors for experimentally determined
structures. In this study, the crystal structure of FucP
transporter (PDB ID 3o7q) was taken as a reference to
compare NMA-based fluctuations of α-carbons with the B-
factors from X-ray crystallography (Figure 3). A RMSF profile
of the five softest modes (mode 1−mode 5) of 45 proteins
with MFS fold from PDB (Figure 3A and Figure S3) exhibited
significant fluctuations in distinct regions (based on residue
numbering): 45−68 (TMH1-2), 182−195 (EC), 240−260
(IC), 280−302 (TMH7), and 392−420 (TMH11; see colored
regions in Figure 3A).
The high peak observed for the region 182−195 for the
GNM-based fluctuations is caused by a significantly extended
TMH1 reaching to the EC region for some transporters (such
as human GluT3 transporter; PDB IDs 4zwb, 4zwc, 4zw9).62
Loop regions possess lower numbers of inter-residue contacts
in the elastic network, which leads to higher flexibility in these
regions. These findings are consistent with other network
models for MFS transporters available in the literature.63
Similarly, large fluctuations in region 240−260 (corresponding
to the cytoplasmic region) are likely caused by the presence or
absence of specific IC domains, such as the YAM domain of E.
coli transporter YarjR (PDB ID 3wdo)64,65 or the IC helical
(ICH) domain consisting of three to four helices in sugar
transporters.66,67
Because of the structural ambiguity of extra- and intracellular
regions, structural models of hepatic OATPs generated herein
cover transmembrane regions only. Specifically, our primary
aim was to unravel binding modes for steroid analogs which
are chemically closely related to endogenous substrates of
these transporters (such as DHEA). Interestingly, mode 1 and
mode 2 of NMA show mutual (out-of-plane) shifts in the
upper part of TMH1 and TMH2 (region 45−68). Fluctuation
values of this region are in a good agreement with experimental
fluctuations for the FucP transporter structure (Figure 3A),
and they are located inside the transmembrane core thus they
Figure 3. (A) Root mean square fluctuations of the selected MFS proteins (n = 45) derived from GNMs (blue curves) and from the X-ray structure
of FucP transporter (PDB ID 3o7q, black curve): The experimental root-mean-square fluctuations are indicated in A2 units, while the theoretical
calculations are given in arbitrary units. The regions of fluctuations discussed in the text are marked by colors. The coloring corresponds to specific
regions in the MFS structure, as shown in panel B: (i) top view with transmembrane helix numbering and (ii) side view.
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could have an impact on ligand accessibility and binding. The
other (albeit less pronounced) TMH motions are located in
the upper part of TMH7 (280−302) and TMH11 (392−420).
Again, the fluctuations of these regions share corresponding
mode shapes with B-factors from experiments (Figure 3A).
These findings prompted us to generate alternate conforma-
tions of the FucP template (PDB ID 3o7q) along mode 1 and
mode 2, reflecting fluctuations in TMH1, TMH2, TMH7, and
TMH11. Specific settings for conformational sampling of the
template (including the implicit membrane model) can be
found in the methodological section (Conformational
Sampling of the FucP Template section).
By reordering sequence- and structure-based matrices
according to the “dynamics-based” similarities, a cluster of
analogous proteins (n = 16, Figure S4) was identified.
Interestingly, some of the dynamically related proteins (PDB
ID 4m64, 3wdo, 4gc0) were predicted by the pGenThreader
algorithm as suitable templates to model hepatic OATPs
(Table S5). These findings show that the structural templates
individually predicted by fold recognition tools are related not
only sequentially and structurally, but also dynamically, which
increases the confidence in fold recognition methods for
detecting valuable templates. For this study, however, no better
suited template was detected by this method for modeling
hepatic OATPs.
Ensemble Docking into OATP1B1, OATP1B3, and
OATP2B1 Structural Models. Studying the ROC curves at
EF1% for the top five models for OATP1B1 (AUC = 0.68−
0.83, EF1% = 0.0−5.0%), OATP1B3 (AUC = 0.75−0.94,
EF1% = 18.5−23.8%), and OATP2B1 (AUC = 0.50−0.70,
EF1% = 0.0−6.04%), differences in the model performances
become obvious (Figure S5B). The models’ abilities to
separate highly actives from inactives/decoys performed best
for the OATP1B3 models, despite a smaller data set of actives
when compared to OATP1B1 (25 actives vs 57 actives). This
phenomenon can be explained by the fact that in case of
OATP1B1 docking 1223 decoys from DUD-E have been
added to the set of measured inactives, whereas for OATP1B3
docking only measured inactives (n = 900) were used for
ligand enrichment calculations. The ROC curves of the top
OATP1B1 models are flatter since obviously the decoys are
more often falsely classified as actives (false positives) than the
measured inactives. The comparably least performing models
were those for OATP2B1, which can be explained by the small
overall compound set for docking (only 12 highly actives, 153
inactives, 279 decoys) and a (relatively) weaker cutoff for
defining activity that was used in this case (≤5 μM).
Interestingly, a certain trend between AUC values and the
radius of gyration of the OATP structural models was
observed. An example is given in Figure S5A for OATP1B1
models. Similarly, an increased pocket volume of the
translocation pore is related to an increase in AUC values.
The five prioritized models for OATP1B1, OATP1B3, and
OATP2B1, differ in terms of their 3D structure from the initial
template conformation (average RMSD of 2.8 Å for
OATP1B1, 3.1 Å for OATP1B3, and 3.2 Å for OATP2B1;
Figure S5C). Specifically, correlated movements of TMH1 and
TMH2 (out-of-plane motion), as well as the fluctuations in the
upper part of TMH7 and TMH11 (opening the central cavity,
possess the highest deviation from the initial template (up to
5.9 Å for TMH2 in OATP2B1). These observations indicate
that the models might benefit not solely from the increased
ligand accessibility (as evidenced by the increase of the radius
of gyration and pocket volume compared to the initial template
structure), but also from the specific directionality of TMH1
and TMH2, which in turn impacts geometry of the N-terminal
domain. In addition, all three prioritized models for the
different OATP transporters possess an equivalent protein
conformational state (open-to-out state with an TMH1/2 out-
of-plane shift, see Figure S5C). These findings suggest that
OATP selectivity is likely driven by subtle variations in amino
acid sequences rather than by significant differences of protein
conformations of the three transporters.
The final structural models used in this study are shown in
t h e G i tHub Repo s i t o r y (h t t p s : / / g i t hub . c om/
AlzbetaTuerkova/EnsembleDoc) and are depicted in Figure
S6). An overview of amino acid residues spanning the different
transmembrane regions in the three transporter models is
given by the amino acid sequence alignment depicted in Table
S3. Residues that are conserved across the three transporters
are marked in this table.
Shared and Distinct Interactions of Steroid Analogs
with Hepatic OATPs. Analyzing common and distinct
binding modes of the three related transporters can be carried
out systematically by pose clustering and frequency analysis of
transporter-ligand interactions. Cluster analysis yielded 15
distinct clusters for OATP1B1, 9 distinct clusters for
OATP1B3, and 9 distinct clusters for OATP2B1, respectively
(Tables S7−S9). Clusters per transporter were prioritized on
the basis of both the number of poses per cluster (compounds
may appear more than once in a single cluster) and the
number of unique compounds per cluster. Filtering for clusters
that possess more than 50% of the actives per respective
transporter, three distinct clusters for OATP1B1 (85%, 65%,
and 55% of unique compounds), two distinct clusters for
OATP1B3 (100% and 83% of unique compounds), and one
single cluster for OATP2B1 (94% of unique compounds) were
retained for further investigations (the location of the
respective clusters in the transporters is depicted in Figure 4).
Next, protein−ligand interaction fingerprint (PLIF) analysis
gave insights into protein−ligand interactions which are shared
Figure 4. Sites of steroid binding for the enriched clusters of docking
poses in the respective transporters (visualized as transparent van der
Waals surfaces): (B) OATP1B1, (C) OATP1B3, and (D) OATP2B1.
Enriched clusters are shown in different color grades. For OATP1B1,
a top view of the protein with numbered TMHs is included for better
orientation (A).
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across the three transporters and those that are specific for a
certain transporter (Tables 2 and S9 and Figures S7−S9).
Studying the top three ligand clusters in OATP1B1, it
becomes obvious that many amino acids are shared (or
overlapping) between the clusters (e.g., 8 out of 19 residues are
shared among all three clusters, see Table 2). The two top-
ranked clusters in OATP1B1 (accommodating 85% and 65%
of the docked compounds, respectively) reach into the central
cavity of the transporter, being enframed by TMH5, TMH7−
8, TMH10−11. The third cluster (55% of docked compounds)
is located closer to the N-terminal domain of the transporter
and is lined by TMH1−5 (Figure S7).
In OATP1B3, the top-ranked cluster interacts with residues
from TMH1−5, (and partly TMH7 and TMH11), similarly to
the third cluster in OATP1B1. The second prioritized ligand
cluster for OATP1B3, however, is located a bit closer to the
central cavity, lined by TMH1, TMH2, TMH7, and TMH10−
11. Here, even more residue interactions are shared among the
two ligand clusters (14 out of 17), making a strict separation of
the observed binding modes even more difficult for this
transporter (Figure S8).
In contrast to OATP1B1 and OATP1B3, OATP2B1 ligand
cluster analysis did only prioritize a single binding site near the
N-terminus (interacting with residues from TMH1−5) with
94% of active ligands docked into this site (Figure S9).
Transmembrane Helices of Hepatic OATPs Stabilized by
Salt Bridges. Across all three transporters, there is only a single
conserved amino acid residue that was prioritized during
steroid docking: GLU74 (in OATP1B1 and OATP1B3)/
GLU95 (in OATP2B1) at TMH2 (Table 2 and Figure S10).
The importance of GLU74 and other residues at TMH2
(ASP70, PHE73, GLY76) for E-3-S transport by OATP1B1
has previously been confirmed by mutagenesis studies.
Mutation of these residues to alanine led to a significant loss
of E-3-S uptake activity. Li et al.27 have postulated the role of
GLU74 for transport function to be mainly acting as a
stabilizing factor for the binding site by formation of a salt
bridge with a nearby positively charged amino acid.
In the generated protein models from this study, the
formation of intramolecular salt bridges by GLU74/95 with a
positively charged residue from a TMH lying opposite of
TMH2 was consistently found in all the three transporters. In
OATP1B1 and OATP2B1, we observed salt bridge formation
of GLU74/95 with ARG580/607 on TMH11 (OATP1B1/
OATP2B1) while in OATP1B3, the intramolecular interaction
was formed with LYS49 on TMH1 instead (Figure S11).
In OATP1B1 and OATP1B3, ARG580 was identified as an
important functional residue and postulated to be either
involved in substrate binding or to be part of the translocation
pathway.29,68 We did not observe direct steroid interactions
with this positively charged residue in OATP1B1 and
OATP2B1 in our study (which is obviously hindered by the
formation of intramolecular interactions), but only in
OATP1B3 (see Tables 2 and Table S9).
In OATP1B1, LYS41 (TMH1), and GLU185 (TMH4) are
forming an additional stabilizing salt bridge (Figures S11 and
5A−E). These observations point to the importance of
positively charged residues in the substrate translocation pore
as also hypothesized by Meier-Abt et al.22
It has to be emphasized that the observed differences in salt
bridge formation between the transporters cannot be attributed
to differences in amino acid residues of the salt bridge forming
interaction partners. As seen from Table 2, all of the
Table 2. Key Amino Acid Residues Involved in Ligand
Binding Considering Prioritized Clusters Onlya
aPrioritized clusters are indicated by colored circles next to the
residues: white, 1st enriched OATP1B1; gray, 2nd enriched
OATP1B1; blue, 3rd enriched OATP1B1 cluster; dark pink, 1st
enriched OATP1B3 cluster; light pink, 2nd enriched OATP1B3
cluster; green, top enriched OATP2B1 cluster. Residues that are
reported in the literature to be important for transport activity are
highlighted in gray color. Residues that appear to be involved in
binding of steroid analogs with a higher frequency in this study (at
least 10% of all poses or interaction partners for the respective
transporter) are marked in bold font. TMH numbers are annotated in
the left column.
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mentioned residues are conserved across all three transporters.
It is tempting to speculate that the salt bridges formed in the
respective final selected models are just reflecting one possible
plausible intramolecular interaction state.
Commonalities and Differences of Steroid Analog Bind-
ing to OATP1B1 and OATP1B3. Overall, for steroid analogs
with OATP1B1 activity, no prominent interactions (at least
10% of all interactions) with residues at TMH1, TMH5, and
TMH11 occurred in our study, while for steroids with activity
on OATP1B3, residues at TMH1 (LYS41, LYS49), TMH4
(GLU185, VAL189), TMH5 (ASN213), and TMH11
(MET577, ARG580) are among the main interacting partners
(see Tables 2 and S9). In experimental studies, LYS41 and
ARG580 have been shown to play a role in transport activity in
both OATP1B1 and OATP1B3.29,68,69 OATP1B1 active
steroids are mainly showing TMH2 (ASN77), TMH4
(ASN178 and ARG181), TMH7 (THR345) and TMH10
(GLY552) involvement in our study (see Tables 2 and Table
S9). ARG181 was found to be a functionally important residue
in OATP1B1, indicated by site-directed mutagenesis studies.70
Inspecting docking poses of several strong OATP1B1
inhibitors (E-3-S, lithocholate, and cholic acid methyl ester)
in OATP1B1, we could observe a relatively consistent pattern
of binding orientations in the central as well as in the N-
terminal binding cavity. In general, the ligands appear to be
vertically oriented in OATP1B1, whereas in OATP1B3 we
observed a horizontal orientation of OATP1B3 binders
(digoxin, lithocholate, and cholic acid methyl ester) and a
less consistent binding pattern (Figures 5, 6, and S12). As
pointed out in the previous paragraph slightly different
orientations of dual OATP1B1/OATP1B3 inhibitors (e.g.,
lithocholate, cholic acid methyl ester, beclomethasone) in the
analogous cavities of the two transporters are likely caused by
the different intermolecular salt bridge formations that force
the ligands into certain orientations due to differences in
pocket accessibility. As seen from Figures 6A−E and S12D−E,
the salt bridge LYS49-E74 (TMH1-TMH2) in OATP1B3
restricts the N-terminal pocket in a way that the horizontal
orientation is favored.
Differences in the interactions with amino acid residues of
dual OATP1B1 and OATP1B3 inhibitors (lithocholate, cholic
acid methyl ester) are shown in Figures 5 and 6 for both the N-
terminal and central binding cavities in both transporters,
highlighting the above-mentioned main contributing residues.
To relate subtle differences of amino acid side chain nature
and orientation in the binding pockets and their different
accessibility for steroidal compounds in OATP1B1 and
OATP1B3 to ligand selectivity, we examined poses of the
two selective steroidal compounds E-3-S (OATP1B1 selective)
and digoxin (OATP1B3 selective) in more detail.
We identified an interaction of E-3-S with Y352 (TMH7) as
a potential reason for OATP1B1/OATP1B3 selectivity. The
side chain hydroxyl group of Y352 interacts with E-3-S through
hydrogen bond formation, which in turn leads to an
orientation of E-3-S, where the ligand is deeply buried in a
hydrophobic cavity (Figure S13). In OATP1B3 the hydrogen
bond formation with TYR352 is disabled (PHE at the same
position). The hydrophobic pocket forming residues include
the nonconserved VAL349 in OATP1B1 (SER in OATP1B3)
and the conserved ILE353. Interestingly, ILE353 is a known
site of OATP1B1 single nucleotide polymorphism
(ILE353THR) related to a decreased OATP1B1 transport
activity. Other steroidal compounds also adopt a similar
binding mode where TYR352 acts as a hydrogen bond donor/
acceptor (in total a decent amount of 7% of all poses interact
with this residue).
Digoxin is a cardiac glycoside with a chain of three sugars in
position R3̅ of the steroidal ring, which is selectively recognized
by OATP1B3. The sugar moiety is buried deeply in the N-
terminal domain of OATP1B3 interacting with GLY105 (main
Figure 5. Ligand binding to the N-terminal binding site (left panel)
and the C-terminal/central binding site (right panel) in OATP1B1:
Several strong steroidal OATP1B1 inhibitors are shown in the top
view (A and F) and side view (B and G), respectively. Panels C and H
are showing lithocholate (light gray, median bioactivity value [μM] =
0.918)). Panels D and I are showing cholic acid methyl ester (cyan,
median bioactivity value [μM] = 0.20). Panels E and J are showing E-
3-S, which is known to be an OATP1B1 selective inhibitor (orange,
median bioactivity value [μM] = 0.450). Hydrogen bonds are
visualized via black dashed lines. The residues labeled in red were
validated via mutagenesis studies published in the literature. Dotted
surfaces around certain residues visualize van der Waals radii in order
to highlight residues that are forming intramolecular salt bridges
between protein residues (K41, E74, E185, R580).
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chain interaction) and LYS41 (side chain interaction) via the
formation of hydrogen bonds (Figure 6D). An equivalent pose
in OATP1B1 was not retrieved by molecular docking.
However, manually placing digoxin into OATP1B1 at the
equivalent position, it becomes evident that ALA45 (which is a
glycine in OATP1B1) would lead to a steric clash with the
large sugar moiety (Figure 7).
ALA45/GLY45 at TMH1 has previously been reported and
experimentally confirmed to be crucial for cholecystokinin-8
(CCK-8) transport by DeGorter at al.71 Through the loss of
the methyl group by A45G mutation in OATP1B1, an increase
of CCK-8 transport was observed. In our models, the pocket
volume increases in case of OATP1B3 through this amino acid
exchange (551 A3 for OATP1B3 compared to 510 A3 for
OATP1B1 for our models), which leads to better pocket
accessibility.
According to the current state of the art, we can, therefore,
assume that differences in preferences for steroid analog
binding to OATP1B1/OATP1B3 can be attributed to
differences in pocket accessibility in the N-terminal part of
the transporters (tentatively induced by nonconserved residues
in TMH1), as well as to nonconserved amino acids in the
central binding cavity (especially those located on TMH7).
Interactions of Steroid Analogs with OATP2B1. OATP2B1
only has a few residues in common with OATP1B1 and
OATP1B3 when studying the docked interactions with
steroidal compounds, which are all located in TMH1 and
TMH2 (Table 2). This behavior was to be expected due to the
remarkable difference in amino acid sequence identities
between the OATP1B subfamily and OATP2B1 (identity
only around 31%). Interestingly, among the shared inter-
actions, those formed with residues at TMH1 (GLN62,
LEU63, and SER66) are shared exclusively with OATP1B3
Figure 6. Ligand binding to the N-terminal binding site (left panel)
and the C-terminal/central binding site (right panel) in OATP1B3:
Several strong steroidal OATP1B3 inhibitors are shown in the top
view (A and F) and side view (B and G), respectively. Panels C and H
are showing cholic acid methyl ester (cyan, median bioactivity value
[μM] = 0.13). Panels D and I are showing digoxin, which is known to
be an OATP1B3 selective inhibitor (orange, median bioactivity value
[μM] = 0.836). Panels E and J are showing lithocholate (light gray,
median bioactivity value [μM] = 6.807). Hydrogen bonds are
visualized via black dashed lines. Residues labeled in red were
validated via mutagenesis studies published in the literature. Dotted
surfaces around certain residues visualize van der Waals radii to
highlight residues that are forming intramolecular salt bridges
between protein residues (E74, K49).
Figure 7. Digoxin helps explain OATP selectivity: Color code:
docked compounds = cyan (carbon), red (oxygen), orange
(phosphorus), OATP1B1 = blue, OATP1B3 = magenta, OATP2B1
= green. van der Waals radii of ALA45 (A), GLY45 (B), and SER66
(C) are visualized via van der Waals radius. Red cross indicated steric
clash of a residue with the ligand. Poses are shown from the top (from
the extracellular part). In addition, the position of ALA/GLY216
(OATP1B1/1B3 nonconserved residue) is depicted in this figure.
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(corresponding to LYS41, ALA42, and GLY45), whereas some
of the main interactions with residues at TMH2 (ASN94) are
shared with OATP1B1 only (corresponding to PHE73).
GLU95 (GLU74 in OATP1B1 and OATP1B3) is the only
shared interacting residue among all three transporters (as
discussed earlier).
The data set of 13α-estrone derivatives (16 compounds in
total; see Table 1) served as a validation set for our procedure.
13α-estrones were chosen since steroids are highly enriched
among OATP substrates, and furthermore the sterane core
allows various modifications helping to reveal structure
function relationship.
Here, we investigated the inhibitory activity of 13α-estrone
derivatives using the previously validated general OATP1B1,
OATP1B3, and OATP2B1 fluorescent substrate pyranine. In
these measurements, A431 cell lines overexpressing one of the
aforementioned OATPs were used and IC50 values for the
compounds have been determined by measuring transport
inhibition at increasing concentrations of the 13α-estrones.
Since data for OATP2B1 is to date very sparse in the open
domain, especially the new bioactivity measurements on
OATP2B1 are a valuable source of information in order to
better understand OATP2B1-ligand interactions and potential
drivers for selectivity. The latter is in particularly supported by
this new data set, since 5 of the 16 compounds are showing
selectivity toward OATP2B1 (between at least 6-fold differ-
ence and 55-fold difference in activities toward OATP2B1 vs
the other two transporters), and 3 additional compounds are
showing preferential activity toward OATP2B1 (see Table 2).
Phosphonated 13α-estrone derivatives have previously been
reported as strong OATP2B1 inhibitors.52 This group of
analogous compounds shows a consistent binding pattern with
GLN196 (TMH4) and SER66 (TMH1) as main interaction
partners (these two residues are also the main interacting
residues within the whole group of 13α-estrone derivatives in
this study with 41% and 32% frequency, see Table S9).
Whereas the carbonyl oxygen at position R-17 position
typically forms the H-bond interaction with the GLN196
side chain, H-bond formation between the phosphono group
at either R-2 or R-4 position is typically formed with SER66
(or sometimes also with the neighboring GLN62; see Figures 8
and S14). SER66 was reported in literature to be important for
transport of endogenous substrates,72 and it is interesting that
this residue is located at the corresponding position 45 in
OATP1B1 and OATP1B3 (which seems to be important for
differences in binding in these other two transporters; see
previous chapter). Also, GLN62 is an experimentally
confirmed functionally important residue in OATP2B1.72
The most potent pan-inhibitor out of the six phosphonated
13α-estrone derivatives discussed in this study (compounds
11−16) is carrying the diethyl phosphono group in position R-
2 and possesses a benzyloxy moiety at position R3̅ (compound
11; IC50 = 0.18 μM). It is at the same time the most potent
OATP2B1 inhibitor reported in this study. We observed two
possible slightly different binding orientations (occurring with
approximately the same frequency) for this compound both
possessing the R-17-GLN196 interaction. In the first one
(Figures 8D and S15), the diethyl phospho group is oriented
toward the inner site of the N-terminal region and forms H-
bonds with the side chain of SER66 (TMH1) and GLY203
(TMH4, main chain interaction). The benzyloxy moiety is
pointing toward a hydrophobic pocket (enframed by LEU63 at
TMH2, ILE206 at TMH4, and LEU230 and PHE231 at
TMH5). In the second possible orientation the diethyl
phosphono group is interacting with TMH4 exclusively (H-
bond formation with the side chain of GLN207), while the
benzyl-ether moiety is buried more deeply in the hydrophobic
pocket (visualized in Figure S16). In both cases, the
hydrophobic interactions of the benzyloxy moiety with its
environment seems to be a leading cause for the high affinity
observed for this compound since the corresponding 3-
hydroxy and 3-methoxy analogs (compound 13 and 15) are
showing an approximately 17-fold decrease in activity
(compound poses shown in Figure S16). Also, for 13α-estrone
derivatives phosphonated in R-4, we can observe the positive
effect on affinity by introducing lipophilicity in position R3̅
since compound 12 (benzyloxy moiety in R3̅) is the most
active of this series (IC50 = 0.75 μM), followed by compound
16 (methoxy moiety in R3̅, IC50 = 2.74 μM), and compound
14 (hydroxyl moiety in R3̅, IC50 = 10.24 μM).
In general, the R-4-substituted phosphonated 13α-estrone
derivatives are a little less active than the equivalent R-2
phosphonated derivatives (especially obvious when comparing
the compound pairs 11/12 and 13/14 where a 3- to 4-fold
drop in affinity is observed; see Table 1). A possible
explanation for this behavior is a smaller tendency to form
interactions with SER66 in case of R-4 substitution due to
steric reasons. This again highlights the central role of SER66
for OATP2B1 steroid binding. Analogous compounds lacking
a diethyl phosphono moiety are still medium to weakly strong
inhibitors, showing similar binding poses but lacking the
activity determining SER66 interaction (see Figure 8C for
compound 3 and Figure S14F for compound 2).
The majority of the seven halogenated 13α-estrone
derivatives reported in this study also act as potent inhibitors
of OATP2B153 with IC50 ranging from 0.6 to 10.45 μM (Table
1). The position of the halogen substituent seems to play a
crucial role here, with R-2 halogenated representatives
(compounds 4, 5, 7, and 9) showing a higher OATP2B1
activity compared to their R-4 counterparts (compounds 6, 8,
10). Comparing the structural analogs, respectively, reveals a
2.5-fold to almost 12-fold difference of the respective binding
affinities (Table 1). Interestingly, two distinct interaction sites
Figure 8. Docking poses of selected 13α-estrone derivatives with a
benzyloxy moiety in R-3: Top view (A), side view (B), docking pose
of compound 3 (C), and compound 11 (D). Hydrogen bonds or
other polar contacts are visualized by black dashed lines. The residues
labeled in red were validated by mutagenesis studies published in the
literature.
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for 13α-estrone derivatives possessing a halogen at the R-2
(site 1) or the R-4 position (site 2) were identified.
Site 1 is located in the upper half of the N-terminal domain
(lined by TMH1, TMH2, TMH3, and TMH4) with the R3̅
substituent (hydroxyl or methoxy group) of R-2 halogenated
steroid analogs pointing toward the EC part of the transporter
(Figure 9) and THR133 (TMH3) acts as interaction partner
for halogen bond formation. In general, threonine is a known
residue capable of forming halogen bonds via its side chain
hydroxyl group.73 In this study, the likelihood for halogen
bond formation has been evaluated on the basis of X---
O(THR133) distances and C20-X---O bond angles, where X
corresponds to Cl (Figure 9A), Br (Figure 9B), or I (Figure
9C), respectively. Geometric parameters are listed in Table
S10. Bond distances are in the range of 3.2−3.9 Å, while bond
angles range from 131° to 156°. Comparable geometric
parameters were found for available PDB complexes forming
halogen bonds, with typical interaction distances ranging from
2.5 to 6.0 Å, while the interaction angles range from 120° to
180°.74,75 Therefore, we assume halogen bond formation is the
major driver for OATP2B1 interactions with halogenated 13α-
estrone derivatives in “site 1”. In addition, the side chain of
GLN196 has been found to form a H-bond with the hydroxyl
group at position R3̅. The 3-methoxy substituent of compound
4 disables the formation of this interaction leading to a 7-fold
decrease in affinity for compound 4 compared to its hydroxyl
derivative (compound 5). Since GLN196 is nonconserved
(GLY177 in OATP1B1 and OATP1B3), the side chain
interaction is also disabled in case of the other two
transporters.
In site 2 (observed for steroids halogenated at position R-4),
the steroidal core is flipped and the R3̅ substituent is pointing
toward the IC part (Figure S17). Here, GLN207 and GLN196
are acting as H-bond donor/acceptors, interacting with the
hydroxyl group at R3̅ and/or the carboxyl oxygen at R-17,
respectively. Both interactions are side chain interactions with
the amide nitrogen of GLN and are interesting residues to
follow up with experiments since also GLN207 is non-
conserved (ILE188 in OATP1B1 and OATP1B3). SER66
(TMH1) was found as a potential interaction partner for the
R-4 halogenated substituents. However, the bond lengths
(ranging from 3.5 to 4.7 Å), as well as bond angles (ranging
from 80° to 110°) do not appear geometrically favorable for
halogen bond formation (Table S10).
Summarizing the observations from molecular docking of
13α-estrone derivatives into OATP2B1 point to a potential
importance of GLN62, SER66, THR133, GLN196, and
GLN207 in OATP2B1 transport function. Some of these
findings are in accordance with alanine scanning experiments
conducted for TMH1 in OATP2B1.72 Specifically, GLN62A-
LA and SER66ALA mutations decreased binding affinity of E-
3-S and taurocholate, thus showing an involvement of these
two residues in OATP2B1 transport function. The roles of
GLN196, THR133, and GLN207 have not yet been confirmed
experimentally, but since these residues are nonconserved
(compared to the other two hepatic OATPs), they are
certainly interesting residues to investigate in future mutational
studies.
Nonconserved Residues Help Explain OATP2B1 Selectiv-
ity. Studying docking poses of 13α-estrone derivatives in all
three hepatic OATPs suggested structural determinants for
OATP1B/OATP2B1 selectivity of steroid analogs.
For the subset of phosphonated 13α-estrone derivatives, the
ones showing activity on OATP2B1 and possessing a
benzyloxy or hydroxy group in R3̅ (compounds 11, 12, and
13) do also show decent activity on OATP1B1 and OATP1B3
(0.8−5.2 μM). In contrast, OATP2B1-actives with a methoxy
group in R3̅ (compounds 15 and 16) are rather inactive on the
other two transporters (9.5−32.4 μM).
Compounds 11 and 12 which are possessing a benzyloxy
group at position R3̅ are adopting similar vertical binding
modes in OATP1B1/OATP1B3 at the TMH1/TMH2 inter-
face as seen for OATP2B1 complexes. However, an interaction
of the R-17 carbonyl group (with GLN196) is disabled since in
OATP1B1/OATP1B3 GLN196 is exchanged with GLY177.
The second frequently observed side chain interaction in
OATP2B1, formed by SER66 with the diethyl phosphono
group, is also disabled by exchange of this residue to ALA45
(OATP1B1) and GLY45 (OATP1B3). Instead, the R-17
carbonyl group interacts with other residues from TMH4 (e.g.,
ASN178 in OATP1B1). In addition, hydrophobic contacts via
Figure 9. R-2 halogenated 13α-estrone derivatives interacting with
site 1: side view (left panel) and top view (right panel). van der Waals
radii of the halogen substituents and the carboxyl oxygens of THR133
are visualized as dotted spheres. Halogen bonds are visualized by
dashed orange lines. H-bonds are visualized by dashed black lines. (A)
Compound 9 (2-chlorine substituent), (B) compound 5 (2-bromine
substituent), and (C) compound 7 (2-iodine substituent). Color
code: docked compounds = cyan (carbon), red (oxygen), green
(chlorine), brown (bromine), purple (iodine); OATP1B1 = blue;
OATP1B3 = magenta; and OATP2B1 = green.
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its benzoyloxy side chain are providing an explanation why
these compounds are also highly active in OATP1B1 and
OATP1B3 (Figure S18).
Compound 13 seems to exhibit its main interaction in
OATP1B1 and OATP1B3 via H-bond formation of its 3-OH
group with GLU185 leading to moderate activity on these
transporters despite missing hydrophobic interactions. The 3-
methoxy derivatives (compounds 15 and 16) are rather
inactive on OATP1B1/OATP1B3 probably due to a lack of all
main interactions observed for OATP2B1 binding (Figure
S16) with the additional flaw of not being able to form strong
hydrophobic contacts or direct H-bonds via its R3̅ substituent.
Halogenated derivatives show a tendency to be more active
on or even selective (compounds 4, 5, 7, and 9) for OATP2B1.
Interestingly, these selective compounds are all halogenated in
position R-2, whereas the R-4 halogenated compounds
(compound 6 and 8) tend to be also active on OATP1B1
and OATP1B3 although with weak to borderline inhibitory
activity.
In OATP2B1, the formation of halogen bonds for R-4
halogenated 13α-estrone derivatives with SER66 seems less
geometrically favorable than for R-2 halogenated compounds.
Thus, loss of this interaction when binding to OATP1B1 or
OATP1B3 (through replacement with A45 or G45) is not
expected to lead to a drop in affinity. However, in OATP1B1
and OATP1B3, a certain preference of R-4 halogenated
substituents to bind to the central cavity rather than in the N-
terminal domain with only a few distinct interactions have
been observed (e.g., with LYS49, ASN77), leading to their
quite weak activities.
For 13α-estrone derivatives halogenated in R-2 (compounds
4, 5, 7, and 9) reasons why OATP2B1 selectivity occurs could
be manifold. Certainly, the missing halogen bonding partner
(THR133; ALA112 and SER112 in OATP1B1 and OATP1B3,
respectively) as well as the missing GLN196 (GLY177 in
OATP1B1 and OATP1B3) for side chain interactions with the
3-OH group play a big role.
It appears interesting to compare the identified halogen
binding site in OATP2B1 (site 1) to the putative sites in
OATP1B1/OATP1B3 (see Figure S19). Mapping an electro-
static surface onto the transporter structure reveals that the N-
terminal binding pocket is highly positively charged in
OATP1B1/OATP1B3, compared to the OATP2B1. The
increased electrostatic surface in OATP1B1 and OATP1B3 is
caused by the presence of positively charged residues (such as
LYS41 and LYS49), which are replaced by uncharged residues
in OATP2B1. As halogens prefer to bind to a hydrophobic
environment76 the preference for OATP2B1 becomes evident.
Overall, the conclusions drawn from these observations
suggest that selectivity of hepatic OATPs is controlled by a
limited number of nonconserved residues at the TMH1/
TMH2 interface, as well as in TMH4, which can affect specific
interactions as well as pocket size.
■ SUMMARY AND CONCLUSIONS
Molecular modeling of OATP-ligand interactions remains
challenging because of the lack of detailed knowledge about
the protein structure. Here, we present an integrative
computational approach, involving a systematic exploration
of available structures with MFS-fold by normal-mode analysis,
construction of multiple OATP models based on alternate
conformations of selected templates, prioritization of the
models on the basis of enrichment docking, and an in-depth
analysis of molecular interactions for steroid analogs.
Signature dynamics of MFS proteins shows conserved
fluctuations of specific protein subdomains. Among others,
an increased flexibility at the TMH1/TMH2 interface was
found to be an important determinant which contributes to the
intrinsic dynamics of MFS proteins. These findings suggest
functional importance of the TMH1/TMH2 interface. There-
fore, the selected structural template (here: FucP transporter)
was sampled along these modes in such a way that the final
conformational ensemble covers movement of TMH1 and
TMH2 helices (and TMH7 and TMH11 to a lesser extent).
The calculated network models of the template were
subsequently used to build OATP structural models in
different conformations. Enrichment docking of a large data
set retrieved from the open domain (spiked with decoys from
DUD-E database) was employed to validate the structural
models on the basis of their ability to enrich known actives.
Top prioritized models for OATP1B1, OATP1B3, and
OATP2B1, are showing an out-of-plane shift of their
TMH1/TMH2 helices. Structural models exhibit a different
shape of the N-terminal binding site compared to the ones
generated on the basis of the initial template structure.
Interestingly, by retrospective redocking of steroid analogs into
the models based on the initial template structure, the
established binding modes for steroids could not be fully
reproduced leading to distinct binding modes which did only
partially correspond to experimentally proven ligand-protein
interactions. This finding indirectly proves our strategy to be
valid and useful.
Also, earlier mutational experiments for OATP1B1 have
shown an involvement of residues at TMH1 (LYS41, GLY/
ALA45, LYS49)71 and TMH2 (ASP70, PHE73, GLU74, and
GLY76)77 in the transport of natural substrates (mostly E-3-S
or taurocholate). Similarly, alanine scanning of TMH1 on
OATP2B1 helped identify key residues (VAL52, HIS55,
GLN59, ALA61, GLN62, SER66, and LEU69) implicated in
the transport of E-3-S and taurocholate.72 Thus, interactions of
ligands with the TMH1/TMH2 interface seem to be of high
relevance, as also shown by the docking results for steroid
analogs in this study.
Docked steroids generally show orientational versatility in
the binding sites. Specifically, the R-3 and R-17 substituents
are capable of forming most of the key interactions.
Cluster analysis reveals two distinct sites for OATP1B1/
OATP1B3one site in the central cavity and one N-terminal
binding site. Experimental data showed that several steroids
(such as E-3-S) exhibit biphasic kinetics, which led to the
identification of low- and high-affinity binding sites. Specifi-
cally, Li et al.27 have shown that the alanine mutants of ASP70
in OATP1B1 affect both low- and high-affinity components,
while PHE73, GLU74, and GLY76 only affects a single site.
ASP70 is located in the upper part of TMH2, thus being
partially involved in both the N-terminal binding site and the
central cavity. The other mutated residues are largely oriented
toward the central cavity. In another study on OATP1B1,
LYS41, and LYS49 (both located at THM1) showed impaired
Km values at the high- and low-affinity binding site of E-3-S,
respectively. Moreover, LYS41ALA mutation led to similar Km
values compared to the wild-type transporter for the low-
affinity site of E-3-S, thus suggesting that LYS41 is only
implicated in a single (high-affinity) binding site. In contrast,
LYS49ALA mutation affected the low affinity component of E-
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3-S. By comparing these findings to our OATP structural
models, we reveal that LYS41 is buried in the N-terminal
binding region, while LYS49 is exposed more toward the
central cavity of the transporter. Overall, the experimental data
reported in literature suggest that the N-terminal region might
correspond to the high-affinity binding site for steroids, while
the central region represents the low-affinity binding site.
However, to fully assess which one of the two regions
identified in this study might represent the high- or low-affinity
site, free energy calculations have to be undertaken in future
studies.
For selecting the best model for steroid docking into
OATP2B1, a data set largely lacking steroidal structures from
the open domain was used for the enrichment docking
procedure. By this procedure an unbiased structural model, not
trained to recognize specifically steroids, could be obtained.
The in-house data set with 16 13α-estrone derivatives served as
a validation set for all three transporters but was especially
effective in case of OATP2B1, since 14 compounds of this data
set are showing strong (0.18 μM) to medium inhibitory
activity (8.39 μM) toward this target (with the exception of
13α-estrone and compound 10). In contrast to the other two
transporters, OATP2B1 shows a single, N-terminal binding
site, for interactions with steroid analogs. However, we have to
emphasize that the conclusions drawn for OATP2B1 might be
affected by the limited structural diversity of the OATP2B1
data set. By comparing interactions adapted by OATP1B1 and
OATP1B3 in the N-terminal binding site, differences in ligand
accessibility appear to be the main cause for variations in
ligand binding. This is partly affected by differently formed salt
bridges in the cavity, as well as by the replacement of alanine
(OATP1B1) at positions 45 and 216 to glycine (OATP1B3),
which leads to disparities in pocket geometry. In OATP2B1, a
single N-terminal binding site at the TMH1/TMH2 interface
accommodates 13α-estrone derivatives with OATP2B1
activity. A distinct halogen binding site with the likelihood of
halogen bond formation in the upper part of the N-terminal
half was identified (at THM3). The corresponding halogen
binding site was not found in OATP1B1 and OATP1B3, likely
due to replacement of THR133 (in OATP2B1) to ALA112 (in
OATP1B1) and SER112 (in OATP1B3), which might explain
selectivity or stronger binding affinity toward OATP2B1 for
halogenated compounds Moreover, OATP2B1-specific binding
of halogenated 13α-estrone derivatives likely happens because
of the different compositions of the electrostatic surface in
OATP1B1/1B3 (positively charged) versus OATP2B1 (hydro-
phobic). As a follow up study, we plan to perform quantum
mechanics optimization of the binding modes possessing
halogen bonding.
Interestingly, a single residue at TMH1 (residue number 45
in OATP1B1/1B3, 66 in OATP2B1) seems to play a role as
OATP selective switch given its role as a steric hindrance and
ability to adopt hydrogen bonds. In this Article, chemical
specificity was exemplified, for example, for phosphonated
13α-estrone derivatives by their ability to form a hydrogen
bond with SER66 in OATP2B1 (but not with ALA45 or
GLY45 in OATP1B1/1B3). Steric effects are potentially the
reason for digoxin selectivity toward OATP1B3, where the size
of the binding site is crucial for accommodating its bulky
substituent at position R-3 of the steroidal core. As the N-
terminal binding site in OATP1B3 possesses the highest
volumegiven the loss of the side chain at position 45 and
216, respectively (both GLY)the OATP1B3-selective bind-
ing of digoxin can be explained. The role of residue number 45
for OATP1B1/1B3 selectivity was previously confirmed by
mutational studies replacing GLY45 (OATP1B3) to ALA45
(OATP1B1) and vice versa.71 Herein, we also found an
indication that binding of steroids to SER66 in OATP2B1
could drive activity toward this transporter (as also shown in
OATP2B1 mutational studies),72 and that ALA45/GLY45/
SER66 might be responsible for driving selectivity of steroid
analogs across the three hepatic OATPs.
The TMH1/TMH2 interface has previously been identified
as an essential substrate binding cavity for different types of
MFS proteins, including the POT family of oligopeptide
transporters.78 In future studies, different transporters with
MFS fold should be explored to investigate whether ligand
recognition at the N-terminal domain of MFS transporter
represents a consistent pattern.
Apart from the interesting interactions happening at
TMH1/TMH2, we also observed a crucial involvement of
nonconserved residues at TMH3 and TMH4, especially
THR133 in OATP2B1 (ALA112/SER112 in OATP1B1/
OATP1B3), GLN196 (GLY177), and GLN207 (ILE188).
These are interesting residues to follow up on with mutational
studies since our computational experiments are pointing
toward their important roles in conferring OATP2B1
selectivity.
With this study, we ultimately contributed to the knowledge
about structural determinants of steroids’ binding to hepatic
OATPs, using a rigorous computational protocol for
generating structural models, followed by the comparative
analysis of important ligand interactions at the identified
binding sites. Insights about interactions of steroid analogs
with OATP1B1, OATP1B3, and OATP2B1 are contributing to
the knowledge of compound requirements for the design of
new chemical probes, which can further elucidate the
physiological role of these emerging transporters.
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A.; Zdrazil, B.; Özvegy-Laczka, C. Structural Dissection of 13-
Epiestrones Based on the Interaction with Human Organic Anion-
Transporting Polypeptide, OATP2B1. J. Steroid Biochem. Mol. Biol.
2020, 200, 105652.
(54) Mysinger, M. M.; Carchia, M.; Irwin, J. J.; Shoichet, B. K.
Directory of Useful Decoys, Enhanced (DUD-E): Better Ligands and
Decoys for Better Benchmarking. J. Med. Chem. 2012, 55, 6582−
6594.
(55) Tuerkova, A.; Zdrazil, B. A Ligand-Based Computational Drug
Repurposing Pipeline Using KNIME and Programmatic Data Access:
Case Studies for Rare Diseases and COVID-19. J. Cheminf. 2020, 12,
71.
(56) Bemis, G. W.; Murcko, M. A. The Properties of Known Drugs.
1. Molecular Frameworks. J. Med. Chem. 1996, 39, 2887−2893.
(57) Molecular Operating Environment (MOE), MOEsaic, PSILO.
Chemical Computing Group. https://www.chemcomp.com/Products.
htm (accessed 2021-03-27).
(58) Wagner, J. R.; Sørensen, J.; Hensley, N.; Wong, C.; Zhu, C.;
Perison, T.; Amaro, R. E. POVME 3.0: Software for Mapping Binding
Pocket Flexibility. J. Chem. Theory Comput. 2017, 13, 4584−4592.
(59) Bacsa, I.; Herman, B. E.; Jójárt, R.; Herman, K. S.; Wölfling, J.;
Schneider, G.; Varga, M.; Tömböly, C.; Rizňer, T. L.; Szécsi, M.;
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Várady, G.; Szakács, G.; Bakos, É.; Özvegy-Laczka, C. Identification of
Novel Cell-Impermeant Fluorescent Substrates for Testing the
Function and Drug Interaction of Organic Anion-Transporting
Polypeptides, OATP1B1/1B3 and 2B1. Sci. Rep. 2018, 8, 2630.
(61) Székely, V.; Patik, I.; Ungvári, O.; Telbisz, Á.; Szakács, G.;
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